Logo
Kromek Investor Hub

Investor Q&A Write-Up - September 2026

Investor Q&A Write-Up, September 2026

On Monday 21st September, Kromek Group hosted a live investor Q&A session, following release of Kromek Group plc's FY2026 final results (year ended 30 April 2026). All questions were answered by Arnab Basu, Chief Executive Officer, and Claire Burgess, Chief Financial Officer.

Revenue & Growth Outlook

  1. What are the revenue expectations for FY2027?

Burgess: In line with market expectations. Kromek is covered by two brokers — house broker Cavendish and one other — and the averaged consensus is £30.3 million.

  1. What top-line growth rate should we model for the next three to five years?

Basu: The company has guided to £60 million of revenue in the medium term, which it defines as FY2030/31. The shape of that growth curve depends on customers' own growth plans, and Kromek will start sharing a trajectory from the half-year results. Growth is expected to continue well beyond that point, into the 2030s and towards 2040, as customers grow their own portfolios.

  1. Cavendish forecasts FY2027 revenue of £30.5 million, down from an earlier £27.1 million estimate. Given licence revenue falls to £1 million in FY2027, that implies non-licence revenue growing from £13.9 million in FY2026 to roughly £29.5 million — a sharp acceleration on top of already-strong 36% growth in FY2026. Where does that growth come from?

Basu: Growth is coming from both divisions. In Advanced Imaging, existing customers are ramping up revenue, and new revenue is starting to come through from the photon-counting CT (PCCT) market — the larger of the two medical imaging markets Kromek serves — alongside continued growth in bone mineral densitometry and other applications. In CBRN, the company has invested in commercial capability, appointing Michael Stevenson as Director of Commercial and Strategy to build out channels. While revenue has traditionally been concentrated in the UK and US, near-term pipeline is now developing across other NATO countries, parts of the Middle East and parts of Asia.

  1. Can you give more meaningful guidance for FY2027, and more importantly indicate how things will be significantly better in FY2028?

Basu: FY2027 guidance of £30.3 million is already in the market, but the underlying business — excluding the Siemens enablement programme — is growing significantly. The medium-term target remains £60 million of revenue at a 30% EBITDA margin, and further guidance on the trajectory to that point will follow over the coming months.

Order Visibility, Backlog & Contract Structure

  1. Will the board commit to greater visibility? Could Kromek disclose aggregate contracted backlog, expected delivery periods, and the proportion of current-year revenue covered by firm orders, separately for Advanced Imaging and CBRN?

Basu: The board recognises investors' need for more granular detail, though some disclosure is limited by customer commercial sensitivity. Kromek publishes a visibility chart around January, aligned to the half-year results, categorising revenue as contracted, likely-but-not-yet-contracted, and pipeline for each segment. The two segments differ in nature: Advanced Imaging is OEM component supply (imaging sensors and detectors) with long design-in cycles but very long resulting relationships — the Spectrum Dynamics contract, for example, runs seven years, and once designed into an OEM platform Kromek typically supplies for the product's full life cycle, which can be up to 20 years. CBRN — handheld radiation detectors sold to military, border security, first responders and nuclear plant operators — is largely tender or direct-order business through distributors, with delivery cycles from one to two months up to around a year for some tenders. Kromek does not yet disclose a total order book but will continue providing this annual, segment-level visibility, and reiterated comfort with the £30.3 million FY2027 consensus.

  1. Can you specify the number of years of orders you have?

Basu: This sits mainly within Advanced Imaging, where OEM relationships typically run three to seven years per order, though the total supply relationship can extend across a product's full life cycle (up to c. 20 years). In some cases the company has purchase-order visibility up to 36 months ahead, particularly as it gears up for a ramp in SPECT and CT. CBRN orders are shorter-cycle, government-contracted business.

Margins, Cash Flow & Balance Sheet

  1. Return on capital employed fell during the year, and the company struggled to convert profits into cash. What are the principal reasons for this deterioration?

Burgess: EBIT fell as expected, reflecting product mix — high-margin licence revenue was £10 million in the year to April 2026, down from £16.5 million the year before. Underlying business margins are being maintained or improving, with tight control of overheads. Advanced Imaging has a long working-capital cycle, managed through banking facilities and cash invested in the business; this will continue to grow alongside the Advanced Imaging business. An HSBC facility has been arranged to support this, funded within existing facilities.

  1. Looking forward, what is the operational gearing, assuming the company continues to grow sales?

Burgess: The fixed cost base provides a solid platform for growth. Costs will rise modestly as sales grow — more so in Advanced Imaging, less so in CBRN — but at a rate significantly below revenue growth.

  1. What steps is the company taking to get paid faster, to improve the 150+ day debtor position?

Burgess: The average credit period across the group's sale of goods is 55 days. The 150+ day figure likely reflects the Siemens enablement agreement, where revenue is recognised in line with accounting standards ahead of cash receipt tied to contract milestones. At the end of FY2026, roughly £35 million of revenue had been recognised against £32.5 million received under that agreement, creating a debtor balance and explaining the higher headline days-sales-outstanding figure. The company works closely with its customers to manage debtor cycles.

  1. At FY2026 year end you have £4.2 million cash but £5.7 million debt. Why not use some of this cash to pay off the debt?

Burgess: The facility is a revolving credit facility, drawn and repaid through the year in one- to three-month tranches that roll at set points. The higher year-end cash and debt positions simply reflect the timing of receipts and loan durations; £2 million was repaid shortly after year end, and the facility will continue to be repaid and redrawn through working-capital cycles.

  1. Do you expect free cash flow to be positive in FY2027 and the current fiscal year?

Burgess: The underlying business is expected to be cash-generative in FY2027, but working capital is expected to increase, particularly in Advanced Imaging, which has a long cycle (raw material in, ingot growth, processing, then supply to customers). Net debt is therefore expected to rise by the end of FY2027 as working-capital demand increases. This is supported by HSBC working-capital facilities, including an additional £3 million currently being documented — not because the full £9 million is needed on an ongoing basis, but to cover intra-month and inter-month fluctuations alongside the Advanced Imaging working-capital increase.

  1. Can the transition to sustainable cash generation be funded without further shareholder dilution? How resilient is that plan to further OEM or procurement delays, and what level of recurring revenue and cash conversion is required to fund operations and development spend?

Burgess: The HSBC revolving credit facility is sufficient to fund the business for the foreseeable future, with adequate headroom and buffer for fluctuations within the growth plan.

  1. Will management provide regular updates on liquidity headroom and progress towards free cash flow breakeven?

Burgess: Yes — this will continue to be covered as part of full-year and half-year reporting.

CZT Technology, Photon-Counting CT & OEM Relationships

  1. How quickly will your photon-counting technology generate cash profit, and how will you take global market share from Hamamatsu Photonics?

Basu: This is really about the market-wide shift from conventional scintillator-based detectors to CZT-based detectors in photon-counting CT, rather than Kromek displacing Hamamatsu directly — Hamamatsu (which supplies photomultiplier components) and Kromek serve different parts of the detection chain. Kromek is the only independent commercial supplier of CZT remaining in the Western world. The shift has been building for over a decade: Siemens's 2010 acquisition of Acrorad (a CZT company based in Okinawa) was an early signal; GE has introduced multiple CZT-based products since 2018; Spectrum Dynamics is 100% CZT-based; Siemens's own enablement programme confirms its direction; and in CT, Canon's acquisition of Redlen followed the same pattern. All four global tier-1 CT players have now committed to a photon-counting CT direction built on CZT. The underlying driver is demand for better image quality, earlier and more reliable diagnosis, and lower overall cost of care — relevant to both publicly funded systems like the NHS and privately funded systems such as the US — against a backdrop of rising costs from an ageing population and increasing disease prevalence. Kromek expects CZT adoption to keep accelerating over the next five to ten years towards a much larger share of the global market.

  1. Can you give an update on your collaboration programmes with tier-1 OEMs in Advanced Imaging?

Basu: There are four tier-1 OEMs across Kromek's markets. In SPECT, GE and Siemens hold around 90% of the market between them, alongside a handful of tier-2 players. In CT, the four tier-1s are GE, Siemens, Philips and Canon, with GE and Siemens the largest. Kromek works with three of the tier-1 OEMs; Siemens is named publicly through the enablement programme announced in January 2025 (FY2025). It also works with a range of tier-2 OEMs, including named partners Spectrum Dynamics and Analogic. These relationships remain strategic, spanning commercialisation, adoption, product launch and ramp planning, across a market going through a generational shift from conventional to CZT detectors.

  1. What measurable evidence demonstrates a transition to repeatable, commercial revenue?

Basu: Revenue growth itself is one indicator. In Advanced Imaging, design-ins with OEMs such as Siemens and Spectrum Dynamics become embedded in established product lines with little scope for dual sourcing, making repeat revenue relatively predictable. CBRN is different — mainly government customers driven by new or replacement need, with demand rising alongside global defence and national-security spending amid ongoing conflicts and tensions. Key repeat customers include the UK Ministry of Defence (including frontline soldiers) and the US Department of Energy, and the sales pipeline is widening geographically through new channels. Kromek is also moving towards commercialising a biological detection system developed over six to seven years with around £20 million of funding from agencies including DARPA, the US Department of Homeland Security, and UK government/MOD bodies, reflecting a persistent and, in management's view, elevated threat level around unconventional weapons and incidents.

Siemens Healthineers Enablement Agreement

  1. How does the board assess the balance between upfront monetisation under the enablement agreement and the loss of long-term supply opportunity from enabling Siemens to manufacture CZT itself?

Basu: The board discussed this at length. The Siemens deal reshaped the company's near-to-medium-term financial outlook, gave Kromek a platform to grow as the market transitions to CZT, and validated the value of IP built over nearly two decades — validation from a tier-1 player holding 45% of the SPECT market. The enablement programme (£37.5 million paid over four years, with an associated IP transfer) was one part of the deal; a supply contract with Siemens, running at least four years, is the other, and Kromek expects to remain a Siemens supplier for the foreseeable future. The two teams now interact closely on a daily basis, which management views as a broader operational, financial and strategic benefit.

  1. What does Kromek consider its normalised earnings potential once the Siemens enablement agreement is fully replaced by recurring CZT supply and underlying Advanced Imaging growth is reflected in the numbers? Should shareholders expect a material improvement in underlying group EBITDA and cash generation over the next two to three years?

Burgess: The medium-term target remains £60 million of revenue at a 30% EBITDA margin. Growth won't stop there — revenue is expected to keep growing towards 2040 — and the EBITDA margin is expected to be maintained at around that level as the business scales.

  1. How is Kromek converting the Siemens agreement into lasting shareholder value? What tangible commercial outcomes — secured and in progress — has the stronger financial position enabled?

Basu: The agreement delivered technical validation, market recognition from a global SPECT leader, and financial transformation across the balance sheet, revenue and profitability. It reinforces Kromek's position in the supply chain for large SPECT and CT opportunities — particularly CT, which is a substantially bigger market than SPECT. SPECT is already commercial (Spectrum Dynamics, GE's own moves, and now Siemens's enablement-driven entry); photon-counting CT is the larger prize ahead. The deal strengthens existing OEM relationships and supports pursuit of new ones, positioning Kromek as a value-add supplier across a meaningful share of the accessible supply chain in what management describes as a roughly $10 billion end-user SPECT/CT market.

Manufacturing Capacity & Investment

  1. Can management indicate the scale of CZT production volumes expected from Siemens and other OEM customers over the next three years?

Basu: Management won't discuss specific customer plans in detail, but directionally: Kromek currently runs around 150 commercial furnaces plus around 20 research furnaces. By 2030/31, based on demand OEM customers are currently articulating, the company expects to be running somewhere between 600 and 1,000 furnaces across all its OEMs. This represents a significant increase in volume, capacity and infrastructure. Consistent with prior guidance, the associated capex is expected to be funded by customers rather than Kromek's own balance sheet, and this is the subject of active discussions with customers now.

  1. Does management believe Kromek's existing manufacturing capacity is sufficient to meet potential demand from its current OEM pipeline, or will capacity become a constraint requiring further investment?

Basu: Current capacity is sufficient for this year and into next year. Detailed ramp planning is underway with customers on the rate and timing needed to meet demand, and current capacity alone would not support the £60 million medium-term target — finalising ramp plans with customers, who are central to that demand picture, is ongoing. As above, related capex is expected to be funded by customers rather than Kromek's balance sheet. On the CBRN side, capacity is not a constraint: the business can grow significantly on existing infrastructure, with only nominal additional overhead required.

Corporate Governance, Remuneration & Listing

  1. Why does the share price continually decline year on year? Since the 2013 IPO, how many original directors remain? What chance is there of a recovery, and is there too much dependence on government contracts?

Basu: Management's focus is on delivering the business plan — it did so last year, including the transformational Siemens deal, and has set out a medium-term target of £60 million revenue at a 30% EBITDA margin since last summer. The business has transformed commercially in recent years and management intends to keep executing and growing, which is what it can control; it hopes the market will in time recognise that value. On board composition: Arnab Basu is the only director remaining from IPO, with the rest having changed through the company's normal non-executive director rotation policy — two directors resigned last year and a new director joined. On government dependence: CBRN is inherently government-contract-driven, but Kromek is a globally recognised brand rather than one dependent solely on UK or US government contracts; while revenue concentration has traditionally sat in the UK and US, that is changing through investment in sales and marketing under Michael Stevenson, with early results already visible, and a wider, more geographically spread pipeline is being built.

  1. Has the approach to announcing commercial progress changed? Does the limited flow of substantive contract announcements (RNS) reflect a change in disclosure practice?

Burgess: Disclosure practice hasn't changed — Kromek continues to disclose material contracts. What has changed is the size threshold for materiality: as revenue has grown, a contract such as £200,000, which might once have been material, is no longer material relative to the group's total results. Large contracts will continue to be disclosed, and the company remains comfortable with market expectations for FY2027.

  1. How were Arnab Basu and Berry Beumer rewarded for the Siemens Healthineers deal, and what proportion was taken in shares?

Burgess: Both were targeted on achieving and delivering the Siemens Healthineers deal and were each awarded a £400,000 bonus, as disclosed in the company's reporting. Payment is linked to, and split across, the milestone payments as they are received. In addition, both individuals sacrificed around 85% of that bonus into shares/options, to be awarded over the milestone period.

  1. What is preventing Kromek from moving its listing from AIM to the main market?

Basu: Kromek needs to reach greater scale in both divisions — broadly, the medium-term target of £60 million revenue at a 30% EBITDA margin — before considering a transition. The company is currently sub-scale for the main market, and management's focus is on executing the growth opportunities in Advanced Imaging and CBRN rather than a near-term listing change.

  1. Do you believe Kromek will remain the only independent commercial supplier of CZT?

Basu: Read as a question about remaining independent: yes, that is plan A, B and C. Kromek intends to remain a CZT supplier to the OEM customers it has built relationships with over 10–15 years — Siemens publicly, alongside other tier-1 and tier-2 OEMs — building an operationally excellent long-term supplier position in Advanced Imaging, alongside a radiation/CBRN business serving global security and defence markets.

Share your feedback

Discover